A major 17-year follow up study published in the British Journal of Psychiatry [1] found a 2.84 times (95% CI 2.06–3.90) increased risk of mortality in people with schizophrenia compared to those not so diagnosed, and with each addition of a neuroleptic (antipsychotic) drug, the risk increased another 2.50.
"Mr. Stanley says he has donated nearly $300 million — including about $35 million in 2005 — to Dr. Torrey’s efforts, the bulk of it for research at universities and start-up drug companies."
"After another four months or so on antidepressants, bringing me to a total of 10 months between the steroids and antidepressants, I was suddenly flipped into this hypomania."
By denigrading all non-chemical interventions, by focusing narrowly on drugs and drugs alone, psychiatry has signed away its profession status.
We are, however, very distressed at what appears to us to be a significant discrepancy between your statements and the reality of SAMHSA’s role in implementing the NFC report recommendations, as well as other discrepancies between your statements and SAMHSA’s actions.
In what appears to be a re-run of the Katrina rescue disaster–The New York Times front page report provides yet another example of mindless and heartless shot gun public polices that are being tested on a vulnerable population of citizens:
Internal e-mail exhorts university staff to lobby Congress for increased funds to increase number of children declared mentally ill.
Authors of the American College of Neuropsychopharmacology Task Force on SSRIs and Suicidal Behavior in Youth: their known ties to the pharmaceutical industry
Even Dr. Robet Temple, FDA Medical Policy Director of the Center for Drug Evaluation & Research dismisses the claimed finidings of a flawed, but highly trumpeted recent SSRI study published in the American Journal of Psychiatry. The study was sponsored by the National Institute of Mental Health.
Responding to the AHRP Infomail–Medical Journal Editor Finds Truth Hard to
Track Down (December 27) Eddie Vos,* expert nutrition specialist offers
comments about the13-year ‘"investigation" of alleged research misconduct by
an Indian physician, as reported in the Wall Street Journal (December 27).
Two studies purporting to report “new encouraging” findings about the efficacy and safety of antidepressants—as tested in the “real world”—were published on Sunday by The American Journal of Psychiatry with an accompanying editorial by Dr. Thomas Insel, director of these studies’ funding agency, the National Institute of Mental Health.
New York Times columnist, Paul Krugman, got it right!
The real story behind the crisis at Merck, the Cleveland Clinic, and the medical industrial complex as a whole "is bigger than either the company or the clinic. It’s the story of how growing conflicts of interest may be distorting both medical research and health care in general."
